Isoray Announces Record Third Quarter Fiscal 2020 Financial Results

Record Revenue and Gross Profit Revenue Increased 50% Year-Over-Year RICHLAND, WASHINGTON – May 12, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body,...
When is a change worth the trouble for brachytherapy?

When is a change worth the trouble for brachytherapy?

Gains in engagement, conformal coverage, seamless logistics, planning, and procedural efficiency drive Wisconsin brachytherapy program’s transition to Cesium Blu™. “If it ain’t broke, don’t fix it.” The ageless axiom holds true in so many circumstances that it will...
The Big Reason Why One Team Switched to Cesium Blu Brachytherapy

The Big Reason Why One Team Switched to Cesium Blu Brachytherapy

 “The potential to smooth out our workflow and increase our potential candidate pool for the procedure given the ability to do brachytherapy with Cesium Blu prior to EBRT is a compelling motivation for adding it to our prostate cancer treatment arsenal,”- Dr. Bobby...

Isoray Announces Second Quarter Fiscal 2020 Financial Results

Revenue Increased 16% Year-Over-Year Gross Profit Increased 45% Year-Over-Year RICHLAND, WASHINGTON – February 11, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options...